Symptoms and General Pathology

All Conditions

Neoplasms

Rare Diseases

Recurrence

Glioma

Glioblastoma

Disease Attributes

Astrocytoma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Stereotactic hypofractionated radiation therapy delivered as follows:

* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
* Planning tumor volume (PTV) equals GTV plus 3mm margin.
* the dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
* RT to begin in a maximum of 2 weeks after randomization.

Stereotactic hypofractionated radiation therapy delivered as follows:

* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
* Planning tumor volume (PTV) equals GTV plus 3mm margin.
* the dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
* RT to begin in a maximum of 2 weeks after randomization.

Stereotactic hypofractionated radiation therapy delivered as follows:

* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
* Planning tumor volume (PTV) equals GTV plus 3mm margin.
* The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
* RT to begin in a maximum of 2 weeks after randomization

Stereotactic hypofractionated RT 5x5Gy

Stereotactic hypofractionated radiation therapy delivered as follows:

* Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
* Planning tumor volume (PTV) equals GTV plus 3mm margin.
* The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
* RT to begin in a maximum of 2 weeks after randomization.

Stereotactic hypofractionated RT 5x7Gy

Andre T Chen, M.D. / PhD

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The treatment comprises maximal safe resection followed by radiotherapy and chemotherapy. Despite appropriate management, 90% of the patients will develop relapse or progression. After progression, the median survival is 5.2 months (Stupp, 2009).

The treatment of GBM relapse remains investigational. Reirradiation is an option in selected cases.

The objective of this study is to compare 2 schemes of stereotactic hypofractionated radiotherapy in the management of recurrent GBM.

Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme

Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme

progression free survival as defined by the "Response Assesment in Neuro Oncology Working Group"(Wen, 2010). Briefly progression is defined as:

* increase in 25% of the product of perpendicular diameters of enhancing lesions
* significant increase in T2/Flair non enhancing component
* appearance of new lesions
* clinical deterioration not atributable to other causes other than the tumor or reduction in corticosteroid dose

* toxicity scored by the Common Terminology of Adverse Events version 4
* will be assessed every 2 months or in case of patient hospitalization or visit to the E.R.

* quality of life measured by the "FACT Br" questionary
* will be assessed every 2 months

Spots Global Cancer Trial Database for stereotactic hypofractionated rt 5x7gy